Loyal raises $100M as its canine longevity pill nears FDA approval
What’s the deal? Loyal, a US startup developing drugs to extend dogs’ healthy lives, has raised $100 million in Series C funding as it moves toward FDADealroom has a profile for this one. Try Dealroom → approval. The round was led by Age1Dealroom has a profile for this one. Try Dealroom →, with backing from Baillie Gifford and existing investors.
The company has now raised more than $250 million in total. Its lead candidate, LOY-002, is a daily beef-flavoured prescription pill aimed at senior dogs.
Founder and chief executive officer Celine HaliouaDealroom has a profile for this one. Try Dealroom → launched Loyal in 2019 after working at The Longevity Fund, the predecessor to Age1. She sees canine longevity as both a major pet health market and a path toward human therapies.
Why now? Loyal expects to submit the final requirement for expanded conditional approval of LOY-002 this year. That could start a roughly six-month review for what may become the first lifespan extension drug approved for any species.
Longevity is also drawing more capital. Laura DemingDealroom has a profile for this one. Try Dealroom →, an early backer of Loyal and co-founder of Age1, said the space has become a serious investment category.
The company is running a large clinical trial, with about 1,300 dogs enrolled through 72 veterinary clinics.
What could go wrong? Loyal still must prove it can manufacture LOY-002 consistently at scale. Approval timelines could slip, and regulators may closely scrutinise lifespan claims.
Pricing could affect adoption, even if the company expects the average dog could take the drug for under $100 per month. Translating canine results into human breakthroughs is uncertain.
The signal: Loyal’s $100 million raise shows investor appetite for longevity beyond human biotech. Pets may become an early proving ground for lifespan medicines, with faster trials and strong consumer demand.
If LOY-002 reaches the market, it could open a new category in veterinary care. The race to treat ageing is moving from lab concept to product.
Sources:
Business Wire
Fast Company
Longevity.Technology
FinSMEs
Startup Rise
Image source:
The Daily Texan
J.V.
